Pharmaceutical giant GlaxoSmithKline is to make a major investment in its Montrose site, bringing jobs to the area.
The company says it views the UK as “an attractive location for investment” and has today announced a £275 million investment into three of its manufacturing sites, despite Brexit.
GlaxoSmithKline (GKS) has said the investment will be spread across three of its UK sites - Montrose, Barnard Castle in County Durham and Ware in Hertfordshire.
It said most of the products made at the three sites would be exported.
The firm also said the investment is likely to create new jobs.
Montrose manufactures active ingredients for respiratory, HIV and vaccine products and employs more than 450 staff. This investment of approximately £110 million will provide a new, state-of-the-art facility for the manufacture of respiratory active ingredients.
Andrew Witty, CEO of GSK, who backed the Remain campaign, said: “Today’s announcement reflects further investment to support our pharmaceutical pipeline and meet growing demand for our innovative portfolio of newly launched products.
“It is testament to our skilled UK workforce and the country’s leading position in life sciences that we are making these investments in advanced manufacturing here.
“From their manufacture in the UK, many of these medicines will be sent to patients around the world.”
UK Government Minister Andrew Dunlop said: “It is great news that GlaxoSmithKline is boosting investment in Scotland, and a real testament to the hard work and skills of the workforce in Montrose.
“Above all, it is a clear vote of confidence in the country’s economy, and shows that Scotland and the UK are very much open for business.”
Barnard Castle in County Durham is one of GSK’s biggest secondary manufacturing sites, employing 1,100 people. The site supplies nearly half a million packs of products per day to 140 global markets. The investment announced today of £92 million will fund the construction of an aseptic sterile facility supporting the manufacture of existing and new biopharmaceutical assets in its pipeline.
Ware in Hertfordshire, employs 1200 staff, manufacturing innovative respiratory products. Today’s investment of £74 million will support further expansion of the company’s new Ellipta respiratory inhaler through additional manufacturing capacity at the site.
GSK has a significant manufacturing presence in the UK, with nine sites employing approximately 6,000 people.